{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

Agreement extends major MS database for world scientific community

A new contract between the Multiple Sclerosis International Federation (MSIF) and the Sylvia Lawry Centre for MS Research (SLC) in Munich will extend the availability of the most comprehensive database in the world to scientific study by researchers in the field.

read more

MSIF benefits from Amazon Associates Programme

MSIF has recently joined the Amazon Associates Programme initiative. This means that, if you link from our website to the Amazon website and buy anything, for example to purchase a copy of Multiple Sclerosis: The Guide to Treatment and Management from our Publications page, MSIF receives up to 10 percent of the sale at no extra cost to you.

read more

back to top

Profile of the Month : January 2008

Gerardo Garcia Perales

Home: Madrid, Spain
Age: 42
Diagnosis: 1986
Occupation: Madrid MS Society President, and Spain MS Society Treasurer

English Espanol Francais Russian Italian German

back to top

The role of Vitamin D in Multiple Sclerosis

This study reviews the literature about the role of vitamin D in the prevention and treatment of multiple sclerosis (MS). The authors conclude that vitamin D supplementation may help prevent the development of MS and may be a useful addition to therapy. However, current studies are in small populations and are confounded by other variables, such as additional vitamin and mineral supplementation.

authors: Brown SJ

source: Ann Pharmacother. 2006 Jun;40(6):1158-61. Epub 2006 May 9.

read more

Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis

In this study the authors assess the safety and tolerability of subcutaneous interferon beta-1a at different doses in 24 children with clinically definite multiple sclerosis. Although effectiveness cannot be inferred from this study, the authors observe a significant reduction in the relapse rate at 22 microg, three times weekly, in the relapsing-remitting subgroup.

authors: Tenembaum SN, Segura MJ.

source: Neurology. 2006 Jun 14; [Epub ahead of print]

read more

Fatigue in multiple sclerosis persists over time : A longitudinal study

This study investigates changes in fatigue in a large cohort of MS patients in order to determine the relationship between changes in disability and depression with changes in fatigue severity. The authors show that fatigue in MS persists over time. Changes in mood status but not in disability are related to changes in fatigue in MS patients.

authors: Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X.

source: J Neurol. 2006 Jun 13; [Epub ahead of print]

read more

Prevalence of Multiple Sclerosis Door-to-Door Survey in Maltepe, Istanbul, Turkey

This study investigates the prevalence of MS in the district of Maltepe, Istanbul, Turkey. The prevalence rates ofMS in the Turkish population living in a district of Istanbul are considerably higher than originally thought and similar to those recently recorded in Sicily and Germany.

authors: Turk Boru U, Alp R, Sur H, Gul L.

source: Neuroepidemiology. 2006 Jun 13;27(1):17-21 [Epub ahead of print]

read more

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

This study estimates current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and investigates the effect of disease severity on costs and utility. Consistent with other studies, costs and utilities are significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.

authors: Kobelt G, Berg J, Atherly D, Hadjimichael O.

source: Neurology. 2006 Jun 13;66(11):1696-702.

read more

Imaging of CNS myelin by positron-emission tomography

In this study the authors provide evidence that (11)C-radiolabeled BMB, a synthesized fluorescent molecule, that binds selectively to myelin both ex vivo and in vivo, can be used in vivo to image central nervous system myelin by positron-emission tomography in baboon. These results provide a perspective for developing a brain myelin imaging technique by positron-emission tomography.

authors: Stankoff B, Wang Y, Bottlaender M, Aigrot MS, Dolle F, Wu C, Feinstein D, Huang GF, Semah F, Mathis CA, Klunk W, Gould RM, Lubetzki C, Zalc B.

source: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9304-9. Epub 2006 Jun 5.

read more

back to top

New chairman of Slovakian MS Society

During their recent assemby in Turcianske Teplice, the Slovakian MS Society appointed a new chairman, Mrs Iveta Galikova.

read more

Czech Republic MS Day

The Czech Republic is holding an MS Day on 25 June, 2006, to help raise awareness of MS in their country.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.